A combination of phosphodiesterase type 5 inhibitor and tamoxifen for acute Peyronie's disease: the first clinical signals

Journal Article A combination of phosphodiesterase type 5 inhibitor and tamoxifen for acute Peyronie’s disease: the first clinical signals Get access Selim Cellek, MD, PhD, Selim Cellek, MD, PhD Fibrosis Research Group, Medical Technology Research Centre, Anglia Ruskin University, Chelmsford CM1 1SQ, United Kingdom Corresponding author: Fibrosis Research Group, Medical Technology Research Centre, Anglia Ruskin University, Chelmsford, Essex CM1 1SQ, United Kingdom. Email: selim.cellek@aru.ac.uk Search for other works by this author on: Oxford Academic Google Scholar Matthew Megson, MBChB, Matthew Megson, MBChB Fibrosis Research Group, Medical Technology Research Centre, Anglia Ruskin University, Chelmsford CM1 1SQ, United KingdomUrology Department, University College London Hospital, London W1G 8PH, United Kingdom Search for other works by this author on: Oxford Academic Google Scholar Marcus M Ilg, PhD, Marcus M Ilg, PhD Fibrosis Research Group, Medical Technology Research Centre, Anglia Ruskin University, Chelmsford CM1 1SQ, United Kingdom Search for other works by this author on: Oxford Academic Google Scholar David J Ralph, MS, FRCS (Urol) David J Ralph, MS, FRCS (Urol) Fibrosis Research Group, Medical Technology Research Centre, Anglia Ruskin University, Chelmsford CM1 1SQ, United KingdomUrology Department, University College London Hospital, London W1G 8PH, United Kingdom Search for other works by this author on: Oxford Academic Google Scholar The Journal of Sexual Medicine, Volume 20, Issue 8, August 2023, Pages 1057–1059, https://doi.org/10.1093/jsxmed/qdad083 Published: 04 July 2023 Article history Received: 21 March 2023 Revision received: 18 May 2023 Accepted: 23 May 2023 Published: 04 July 2023